M

Merck

Makes medicines, vaccines and animal treatments

HVAC Maintenance Technician - Operations

Full-TimeDeadline 11/6/26
$71.9k - $113.2k+ Annual bonus + Long-term incentive
Senior, Expert
Associate's
Millsboro, DE, USA
In Person
Building TradesHVAC & Building Systems
No H1B Sponsorship

About the job

Requirements
  • At least five years of experience with heating, ventilation, and air conditioning systems.
  • At least three years of experience working with light and heavy commercial refrigeration equipment.
  • Experience with chillers and cooling towers.
  • Experience with general plumbing and pipefitting work.
  • Experience with electrical controls for HVACR systems.
  • Ability to read and interpret blueprints and schematics for electrical, hydraulic, pneumatic, or mechanical systems.
  • A valid driver's license.
  • A universal refrigerant license.
  • Ability to meet physical requirements, including lifting or carrying up to 50 pounds and working from ladders and elevated platforms.
  • Availability to participate in the on-call rotation.
  • Experience working within Occupational Safety and Health Administration General Industry standards, including hot work and lockout/tagout.
  • High school diploma.
  • Support and operate equipment efficiently and safely in compliance with Good Manufacturing Practices.
  • Knowledge or experience with chilled water systems, computerized maintenance management systems, electrical system troubleshooting, HVAC systems, instrumentation, interpreting electrical drawings, mechanical troubleshooting, plumbing, pneumatic systems, preventive maintenance, programmable logic controller engineering, safety compliance, utilities management, and vendor relationship management.
Responsibilities
  • Install, maintain, troubleshoot, and repair process-control and environmental-control HVAC systems.
  • Own operational performance and regulatory compliance for site HVAC equipment, including ultra-cold freezers and process chillers.
  • Provide timely feedback and coordinate with site customers regarding HVAC system status.
  • Establish and maintain appropriate spare-parts inventories.
  • Support investigations resulting from abnormal equipment performance.
  • Actively support safety initiatives, including shop-floor audits, lockout/tagout, line breaks, and confined-space permitting.
  • Provide training to others as required.
  • Work as part of a team to support the site mission, vision, and goals through efficient and safe equipment operation and compliance with Good Manufacturing Practices.
Desired Qualifications
  • An Associate of Science degree in a technical discipline.
  • Biotechnology or pharmaceutical Good Manufacturing Practice manufacturing industry experience.
  • Experience with -70°C ultra-cold freezers, freeze driers, and liquid nitrogen equipment.
  • Experience with gas furnaces and gas heaters.
  • Experience with biopharmaceutical processing equipment, including freeze driers, ultra-cold freezers, and incubators.
  • Working knowledge of an automated building management system, such as Siemens.
  • Experience supporting a fast-paced manufacturing environment.
  • Experience with computerized maintenance management system utilization.
  • A journeyman card or master HVACR license.
  • Experience with large commercial walk-in coolers or walk-in freezers.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

WebBizMarket
Oct 19th, 2026
Cancer vaccine manufacturing time could shrink.

Cancer vaccine manufacturing time could shrink. Merck's CEO Rob Davis expressed optimism regarding the manufacturing timeline of the company's cancer vaccine developed in collaboration with Moderna. In a recent interview with CNBC, Davis indicated that efforts are being made to shorten the current six-week production period, which could improve patient access to this innovative treatment. The vaccine is personalized, targeting mutations specific to each patient's tumor, which complicates production but is designed to enhance the immune system's ability to combat cancer. Davis emphasized the complexity of the vaccine manufacturing process but conveyed confidence in the collaboration between Merck and Moderna, stating that they have refined the process to ensure timely delivery to patients. Positive preliminary data from a late-stage trial involving melanoma patients has bolstered this optimism, with ongoing investigations into the vaccine's efficacy against other cancers, including non-small cell lung cancer and bladder cancer. In a related development, Merck has inaugurated a new 120,000-square-foot research facility named Advance at its West Point, Pennsylvania campus. This facility incorporates advanced technology aimed at enhancing research and development processes. The launch comes as Merck anticipates the expiration of patents for its flagship drug, Keytruda, which is essential to its revenue model. To mitigate potential revenue loss, the company plans to bolster its pipeline with both internal research and substantial external acquisitions. Merck is also addressing legal challenges regarding the subcutaneous formulation of Keytruda in Europe, where a recent court ruling has affected its market capabilities. Despite these hurdles, the company remains focused on introducing new therapies, including its recently approved cholesterol-lowering medication, Lipfendra. Why this story matters * This vaccine represents a significant advancement in personalized cancer treatment, potentially improving patient outcomes. Key takeaway * Merck and Moderna are committed to refining the manufacturing process of their personalized cancer vaccine, aiming for broader patient access. Opposing viewpoint * Legal challenges regarding Keytruda's subcutaneous formulation could hinder market penetration and affect future revenues.

Spot On Pennsylvania
Oct 16th, 2026
Merck expands near philadelphia as riverside plant winds down.

Merck expands near philadelphia as riverside plant winds down. RIVERSIDE - While Merck is closing its longtime manufacturing operation in Northumberland County, the pharmaceutical company is preparing a major expansion elsewhere in Pennsylvani... Discover more Get Sports Gear Discover more Read Daily News